Successful IOL implantation depends on PCO prevention

Article

Successful IOL implantation in paediatric eyes depends on further advances in PCO prevention

Results of a recent study examining adult autopsy globes show that implants fabricated from hydrophobic acrylic material (AcrySof, Alcon Laboratories) are associated with a much higher rate of posterior capsule opacification (PCO) than previously thought. It had been believed that this IOL was associated with low PCO rates and, therefore, it was being implanted in up to 96% of paediatric cataract surgery cases.

"We now know that the PCO rate is [about] 35%, no different from many other lenses," said Brian E. Zaugg, a medical student at the University of Utah, Salt Lake City, USA, and research fellow with the David J. Apple, MD, Laboratory for Ophthalmic Devices Research, Sullivan's Island, South Carolina, USA. "This puts into question the arbitrary use of only one IOL design in children.

"Our study shows that the postoperative time is actually the major factor associated with PCO development," Zaugg added. "Also considering that, when compared with adult eyes undergoing cataract surgery, paediatric eyes exhibit more rapid lens epithelial cell (LEC) proliferation and the IOL remains in the eye for a much longer duration, paediatric implants will have a much lesser chance to ward off PCO.

Study data

This study, which was conducted with Dr Apple, included 500 cadaver eyes that were post-extracapsular cataract extraction and lens implantation obtained between 2004 and 2007. The focus was on AcrySof IOLs, because according to a 2007 survey conducted by Wilson et al., they represent more than 96% of implants used in paediatric cataract surgery.

The data this far were obtained on the three-piece AcrySof IOLs because the single-piece lens model has only recently become available for accession in the laboratory's autopsy database, Zaugg noted. However the biomaterial used to fabricate the lens has remained unchanged.

"In summary, we have come a long way toward achieving our goal of safe and effective paediatric surgery," Zaugg concluded. "But in both adults and children we do need to attack the root of the problem by finding better means of removing lens material from the capsular bag, for example, using pharmacologic strategies."

Brian E. Zaugg is a medical student at the University of Utah, Salt Lake City, USA and a research fellow with the David J. Apple, MD, Laboratory for Ophthalmic Devices Research, Sullivan's Island, South Carolina, USA. He can by contacted by E-mail: brzaugg@hotmail.com

Mr Zaugg does not hold a proprietary interest in the subject matter.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.